Can you provide the upcoming earnings date for MATINAS BIOPHARMA HOLDINGS I?
MATINAS BIOPHARMA HOLDINGS I (MTNB) will report earnings on 2026-04-13, after the market close.
MATINAS BIOPHARMA HOLDINGS I (MTNB) Forecast, Price Target & Analyst Ratings
NYSEARCA:MTNB • US5768103039
Current stock price
0.57 USD
-0.04 (-6.56%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MATINAS BIOPHARMA HOLDINGS I (MTNB).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.57 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
MTNB was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about MTNB.
In the previous month the buy percentage consensus was at a similar level.
MTNB was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-31 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-10-11 | BTIG | Reiterate | Buy -> Buy |
| 2023-01-31 | HC Wainwright & Co. | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 13, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2025 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 33.3K -78.96% | 3.188M 9,473.57% | 1.096M -65.62% | -100.00% | 23.053M | 122.49M 431.34% | 161.87M 32.15% | 210.87M 30.27% | 549.49M 160.58% | 619.59M 12.76% | |||
| EBITDA YoY % growth | -24.455M -2.25% | -24.234M 0.90% | -23.373M 3.55% | -24.582M 15.32% | -20.4M -3.07% | 5.1M 125.00% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -24.735M -2.18% | -24.59M 0.59% | -23.766M 3.35% | -22.296M 15.16% | -8.313M 58.77% | -36.492M -338.97% | 9.173M 125.14% | 180.78M 1,870.78% | 236.92M 31.05% | 308.74M 30.31% | 457.1M 48.05% | 518.79M 13.50% | |
| Operating Margin | -74,278.68% | -771.33% | -2,168.43% | N/A | N/A | N/A | 39.79% | 147.59% | 146.36% | 146.41% | 83.19% | 83.73% | |
| EPS YoY % growth | -5.50 8.33% | -5.50 | -5.50 | -4.37 24.18% | -1.53 63.31% | -5.10 -233.33% | 1.02 120.00% | 24.99 2,350.00% | 32.13 28.57% | 41.82 30.16% | 61.20 46.34% | 68.34 11.67% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
30.93%
EPS Next 5 Year
57.54%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
MATINAS BIOPHARMA HOLDINGS I / MTNB Forecast FAQ
How do analysts rate MATINAS BIOPHARMA HOLDINGS I (MTNB)?
The consensus rating for MATINAS BIOPHARMA HOLDINGS I (MTNB) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.